The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

INTRODUCTION: Severe haemophilia A (HA) has a major impact on health‐related quality of life (HRQoL). AIM: Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 studies. METHODS: This pooled analysis examines the...

Descripción completa

Detalles Bibliográficos
Autores principales: Skinner, Mark W., Négrier, Claude, Paz‐Priel, Ido, Chebon, Sammy, Jiménez‐Yuste, Victor, Callaghan, Michael U., Lehle, Michaela, Niggli, Markus, Mahlangu, Johnny, Shapiro, Amy, Shima, Midori, Campinha‐Bacote, Avrita, Levy, Gallia G., Oldenburg, Johannes, von Mackensen, Sylvia, Pipe, Steven W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518882/
https://www.ncbi.nlm.nih.gov/pubmed/34171159
http://dx.doi.org/10.1111/hae.14363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518882/
https://www.ncbi.nlm.nih.gov/pubmed/34171159
http://dx.doi.org/10.1111/hae.14363

Ejemplares similares